Amplia Therapeutics Ltd (ASX:ATX) will showcase data from a clinical study into its leading anti-cancer drug candidate at a major cancer conference this year.
An abstract that presents data from Amplia’s phase one clinical trial into its AMP945 formulation has been accepted for presentation and publication at the American Association for Cancer Research (AACR) meeting in April 2022.
The abstract, titled “A Phase 1 trial of AMP945, a potent and selective focal adhesion kinase inhibitor, in healthy volunteers” describes the results from Amplia’s phase one clinical trial of AMP945 in healthy volunteers, which was completed in 2021.
This trial showed that AMP945 was safe and well-tolerated, could be administered orally once a day, and was able to inhibit its intended target, focal adhesion kinase (FAK), in tissue samples taken from participants in the study.
On the back of the successful data from this trial, Amplia intends to initiate a phase two clinical trial in first-line pancreatic cancer patients in early quarter two, 2022.
Amplia’s abstract will be presented at the AACR meeting in New Orleans in early April 2022. The paper will also be published online in the Proceedings of the AACR archive.
Speaking to the upcoming conference, Amplia CEO Dr John Lambert said: “The AACR is one of the most recognised international forums for cancer research and we are delighted that the results of our phase one trial have been selected for presentation at this prestigious meeting.
“We believe the approach we are taking using AMP945 to potentially improve the current standard of care treatment for pancreatic cancer is well supported by our phase one clinical trial data and the results from a number of nonclinical studies we have conducted.”
About Amplia
Amplia Therapeutics is developing a pipeline of focal adhesion kinase (FAK) inhibitors to tackle diseases like cancer and fibrosis.
The pharmaceutical company is working on a suite of drug candidates that combat the FAK signalling protein, which is involved in many cancer defence mechanisms that ultimately reduce the effectiveness of cancer drugs.
By creating inhibitors that disrupt the FAK protein, Amplia hopes to remove the shield that protects cancerous cells and deliver a deadly blow to diseases like pancreatic cancer.
Outside of the oncology space, Amplia’s pipeline also has the potential to combat fibrosis conditions like idiopathic pulmonary fibrosis (IPF), which affects 3 million people worldwide.
With a view to build on past clinical momentum, Amplia will spend 2022 developing its lead drug candidate, AMP945, in a series of phase two clinical studies.